We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Debiopharm S.A., the independent drug-development company specializing in oncology,
endocrinology and niche products, announced that it signed a research collaboration
with NanoCarrier Co., Ltd, a company specializing in the development of drugs
based on their proprietary micellar nanoparticle drug delivery systems (DDS)
technology, to develop a new platinum compound.
PTC Therapeutics, Inc (PTC), a biopharmaceutical company focused on the discovery,
development, and commercialization of small-molecule drugs targeting post-transcriptional
control mechanisms, announced that the company has been awarded a $1.5 million
grant from the Muscular Dystrophy Association (MDA).
MedImmune on Thursday said first-quarter earnings rose, surpassing Wall Street
expectations, on higher sales of its flagship respiratory drug Synagis and improved
gross margins.
Inyx, a specialty pharmaceutical company with a focus on niche drug delivery
technologies and products, announced that its wholly owned subsidiary Inyx Pharma
Limited has been selected by Generics (UK) Ltd, a unit of Merck Generics Group,
a global pharmaceutical company, to produce for worldwide markets a non-ozone-depleting
hydrofluoroalkane (HFA) salbutamol inhaler for the treatment of asthma and other
chronic respiratory conditions.
Dishman Pharmaceuticals & Chemicals Ltd has acquired a Manchester-based
contract research company, Synprotec Ltd, through its 100 percent wholly owned
UK-based subsidiary company Dishman Europe Ltd.
Anthera Pharmaceuticals, a private start-up pharmaceutical company specializing
in serious respiratory and inflammatory diseases, announced it has completed
its Series A Preferred financing and is moving forward under a proven leadership
team.
Molecular Insight Pharmaceuticals Inc. said it raised $28 million in a third
round of venture financing that will enable the Cambridge firm to take its cardiac-imaging
compound into pivotal clinical trials.
Merrimack Pharmaceuticals Inc. said Wednesday it
has completed equity and debt financings totaling $37.3 million. According to
the Cambridge drug company, the financing was made up of a $28.3 million of
Series D preferred stock and a $9 million venture loan.
Novartis has signed a global development and commercialization deal with two
small British firms for a compound to treat lung disease in one of the largest
such transactions in Europe to date.
The FDA will address drug-safety issues during a two-day advisory committee
meeting scheduled for May to explore issues related to the agency's risk assessment
program for marketed drugs.